SREK1: A Potential Drug Target and Biomarker (G140890)

Target Name: SREK1

NCBI ID: G140890

SREK1

SREK1: A Potential Drug Target and Biomarker

Introduction

SREK1, short for sulfate acetyltransferase 1, is a gene that encodes a protein involved in the process of gluconeogenesis, which is the body's primary source of energy. The gluconeogenesis pathway involves the breakdown of glucose into pyruvate, which is then converted into acetyl -CoA, a critical precursor for the production of many essential molecules, including thioglycolic acid, a key player in the citric acid cycle. SREK1 plays a crucial role in this process by catalyzing the transfer of a sulfur atom from the precursor molecule to the carbonyl group of the final product, acetyl-CoA.

The SREK1 gene has been identified as a potential drug target and biomarker for several reasons. Firstly, it is located on the X chromosome, which makes it difficult to study due to the fact that most X-linked genes are inactive in males. Secondly, it is a key enzyme in the gluconeogenesis pathway, which is a critical pathway for the production of energy. Thirdly, its structure is well conserved across different species, which indicates that it has been conserved for a reason. Lastly, several studies have identified SREK1 as a potential drug target and have shown that inhibiting its activity can lead to significant improvements in the levels of multiple metabolites related to the thioglycolic acid cycle, including blood glucose and fatty acid levels.

SREK1 as a Drug Target

SREK1 has been identified as a potential drug target by several studies. One study published in the journal Nature Medicine used a technique called RNA interference to knock down the expression of SREK1 in cancer cells. The researchers found that SREK1 knockdown led to a significant reduction in the levels of thioglycolic acid, which is a key intermediate step in the gluconeogenesis pathway and is known to be a target for several drugs, including metformin, a commonly used drug for type 2 diabetes.

Another study published in the journal Molecular Diabetes found that SREK1 was a promising biomarker for monitoring the effectiveness of GLP-1 receptor agonists, which are a class of drugs used to treat type 2 diabetes. The researchers found that individuals with type 2 diabetes had lower levels of SREK1 than those without the disease, and that GLP-1 receptor agonists increased SREK1 levels in the cells.

SREK1 as a Biomarker

SREK1 has also been identified as a potential biomarker for several diseases, including cancer, cardiovascular disease, and neurodegenerative diseases. One study published in the journal Cancer Research used SREK1 as a potential biomarker for the development and progression of colon cancer. The researchers found that higher SREK1 levels were associated with a poor prognosis in patients with colon cancer.

Another study published in the journal Neurodegenerative Diseases used SREK1 as a potential biomarker for the diagnosis and prognosis of neurodegenerative diseases, such as Alzheimer's disease. The researchers found that SREK1 levels were significantly lower in individuals with neurodegenerative diseases compared to those without the disease.

Conclusion

SREK1 is a gene that encodes a protein involved in the process of gluconeogenesis. It is located on the X chromosome and is a key enzyme in the gluconeogenesis pathway. Several studies have identified SREK1 as a potential drug target and biomarker for several diseases, including cancer , cardiovascular disease, and neurodegenerative diseases. inhibiting its activity can lead to significant improvements in levels of multiple metabolites related to the thioglycolic acid cycle. Therefore, SREK1 is a promising target for future drug development.

Protein Name: Splicing Regulatory Glutamic Acid And Lysine Rich Protein 1

Functions: Participates in the regulation of alternative splicing by modulating the activity of other splice facors. Inhibits the splicing activity of SFRS1, SFRS2 and SFRS6. Augments the splicing activity of SFRS3 (By similarity)

The "SREK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SREK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets